This report was first published by Endpoints News. To see the original version, click here
Gilead Sciences is buying the rest of CAR-T collaborator Arcellx that it doesn’t already own, as its closely watched multiple myeloma cell therapy nears potential approval and launch.
The deal values Arcellx at $7.8 billion, more than double the company’s market capitalization at the end of last week. Gilead already owned about 12% of Arcellx following their initial partnership in 2022 and an expanded deal in 2023.
您已阅读21%（507字），剩余79%（1865字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。